Ear wax removal near Tiverton Devon

Ear wax removal near Tiverton Devon

 

Ear wax removal near Tiverton Devon is available at the Honiton hearing centre. If you are suffering from excessive wax build up in the ear or ears we can come to your aid. Using Microsuction or the traditional irrigation technique, (some call it ear syringing), it only take a few mins to painlessly  remove excess ear wax. Please click here to see how Micro-Suction works via our new online video.

To see how ear syringing works please click here. 

If you live in Tiverton area then contact us for Ear wax removal near Tiverton Devon

Honiton hearing centre also conduct lots of other ear related issues such as hearing tests, dispensing the very latest digital hearing aids along with hearing aid servicing and setting up of new hearing aids after you purchase them. If you need any of our services please book in using our online booking calendar or call Sam on reception.

 

Honiton hearing news:

Philips Hearing Aids Introduced by Demant

Published on 

Philips-Hearing-Aids-Honiton-Hearing-Devon

Honiton hearing Devon

Demant, Copenhagen, Denmark, has announced the introduction of Philips branded hearing aids to the global hearing aid market, according to a press release from the company. A new player, the Philips brand is entering the hearing healthcare market with a complete range of premium hearing aids, accessories, and applications to best serve hearing aid users. Demant states Philips Hearing Solutions will quickly become a trusted brand with hearing care providers and users, as it has great potential around the world to present unique opportunities for hearing care professionals in an ever-evolving market.

In August, Demant  announced a licensing agreement with Philips, which is headquartered in Eindhoven, The Netherlands, to bring Philips-branded solutions to the hearing healthcare market.  Demant (formerly William Demant Holding) is the parent group of Oticon, Sonic, and Bernafon hearing aids, as well as Oticon Medical.

Ear wax removal near Tiverton Devon

“Based on a shared vision of improving the lives of people through innovative healthcare this new cooperation will not only change the way we see hearing healthcare, but also widen the definition of hearing healthcare, supporting healthier lifestyles and active aging,” said Spencer Ramsey, Senior Director of Brand Licensing, Philips, in the press statement. “Combining Demant’s world-leading hearing aid technology with Philips’ global brand presence in healthcare, the cooperation will enrich the hearing healthcare experience.”

The new premium Philips hearing aids—named Philips HearLink—are now available for hearing care professionals in selected countries. The look and feel of the Philips HearLink hearing aids is designed to cater to today’s baby boomer generation with design and usability developed for this expanding market. Philips HearLink users will benefit from connectivity between their hearing aids and the devices they use in their everyday life, such as smartphones and televisions. The hearing aids will reportedly be manufactured by Demant using the Velox-S and Velox platforms, and will be available in a complete range of styles, including RICs, BTEs, ITCs, CICs, and IITs.

Demant President Søren Nielsen provided an overview of the Oticon Opn S and Opn Play at an investor and media presentation.

Søren Nielsen

“The Philips hearing aids will provide users with an innovative, future-proof hearing solution,” says Demant President & CEO Søren Nielsen. “We live in an age where user engagement and digital services are shaping the future of healthcare technology. More and more people are conscious of taking control of their own personal healthcare and are using electronic devices to do so. In this light, Philips Hearing Solutions offers new and exciting premium solutions alongside Philips’ healthcare ecosytem, which will attract interest and generate significant benefits to users, ultimately supporting our valued customer base of hearing care professionals.

Tiverton ear wax removal at the Honiton Hearing centre

“With this partnership, we take connected hearing healthcare to the next level and offer new and exciting solutions within integrated healthcare services to the benefit of both professionals and people suffering from a hearing loss,” continued Nielsen. “Health, caring, and innovation are cornerstones in the vision of both Demant and Philips, which makes the partnership a great match for the future. Furthermore, it will strengthen and add value to both companies’ ambition to improve people’s lives.”

The Philips brand is something of a “back to the future moment” for more seasoned dispensing professionals. Philips was a well-known hearing aid brand in the 1990s, and the company embarked on a technical collaboration with Telex then exited the market just before the turn of the new century when Beltone purchased Philips’ hearing aid technology. The Hearing Review published numerous news and technical articles about Philips technology in the 90s.

Traditionally, hearing aid branding has not played a large role in hearing healthcare; MarkeTrak 9 suggested that less than half of hearing aid users (43%) could identify the brand of their device. However, many experts in the industry believe this is due to change, as more consumers are expected to enter the market and there is continued competition and aggressive marketing among dispensing chains, pharmacies, mass merchandisers, and online retailers. The Philips brand brings with it one of the world’s best known and trusted healthcare and consumer electronics brands.

For further information about Philips Hearing Solutions and a full presentation of the Philips HearLink product range, visit: hearingsolutions.philips.com

Honiton hearing centre, Devon

Honiton hearing centre, Devon

 

 

Honiton hearing centre caters for all types of hearing loss and ear wax removal. Colin Eaton, the lead audiologist at the Keynsham hearing centre has over 15 years audiology expertise to make sure his clients get the best hearing result no matter what the hearing issues are.

Ear wax removal is available by appointment and a limited amount of out of hours appointments are available but please call Sam on reception if you require out of hours.

Comprehensive hearing tests are also available. Please make sure that any ear wax issues are clear before you take the test, if you need ear wax removing prior the test please call reception and make this clear to Sam that you will need ear wax clearing first.

If you are confused on what hearing aids are for and for what type of hearing loss, please watch our new video here that explains why so many different types of hearing aids there are.

 

Honiton hearing centre, News

Researchers Restore Hearing via Gene Therapy in Deaf Mouse Model

Published on 

In collaboration with the universities of MiamiColumbia, and San Francisco, scientists from the Institut Pasteur, InsermCNRSCollège de FranceSorbonne University, and the University of Clermont Auvergne have managed to restore hearing in an adult mouse model of DFNB9 deafness, a hearing disorder that represents one of the most frequent cases of congenital genetic deafness, Institut Pasteur announced on its website. Individuals with DFNB9 deafness are profoundly deaf as they are deficient in the gene coding for otoferlin, a protein which is essential for transmitting sound information at the auditory sensory cell synapses. By carrying out an intracochlear injection of this gene in an adult DFNB9 mouse model, the scientists successfully restored auditory synapse function and hearing thresholds to a near-normal level. These findings, published in the journal PNAS, open up new avenues for future gene therapy trials in patients with DFNB9.

Honiton hearing centre Devon

The left panel is a schematic representation of the human ear. Sound waves are collected by the outer ear made up of the pinna and ear canal. The middle ear, composed of the eardrum and ossicles, transmits sound waves to the inner ear, which features the cochlea – the hearing organ responsible for transmitting auditory messages to the central nervous system. The right panel shows an immunofluorescence image of the auditory sensory epithelium within an injected cochlea. The inner hair cells have been stained for otoferlin in green. Otoferlin is detected in almost all of these cells. The inset is a high magnification area showing an inner hair cell that has not been transduced. © Institut Pasteur

The left panel is a schematic representation of the human ear. Sound waves are collected by the outer ear made up of the pinna and ear canal. The middle ear, composed of the eardrum and ossicles, transmits sound waves to the inner ear, which features the cochlea – the hearing organ responsible for transmitting auditory messages to the central nervous system. The right panel shows an immunofluorescence image of the auditory sensory epithelium within an injected cochlea. The inner hair cells have been stained for otoferlin in green. Otoferlin is detected in almost all of these cells. The inset is a high magnification area showing an inner hair cell that has not been transduced. © Institut Pasteur

Ear wax removal Devon

Over half of nonsyndromic profound congenital deafness cases have a genetic cause, and most (~80%) of these cases are due to autosomal recessive forms of deafness (DFNB). Cochlear implants are currently the only option for recovering hearing in these patients.

Adeno-associated viruses (AAVs) are among the most promising vectors for therapeutic gene transfer to treat human diseases. AAV-based gene therapy is a promising therapeutic option for treating deafness but its application is limited by a potentially narrow therapeutic window. In humans, inner ear development is completed in utero and hearing becomes possible at approximately 20 weeks of gestation. In addition, genetic forms of congenital deafness are generally diagnosed during the neonatal period. Gene therapy approaches in animal models must therefore take this into account, and gene therapy efficacy must be demonstrated following a gene injection when the auditory system is already in place. In other words, therapy must reverse existing deafness. The team led by Saaïd Safieddine, a CNRS researcher in the Genetics and Physiology of Hearing Unit (Institut Pasteur/ Inserm) and coordinator of the project, used a mouse model of DFNB9, a form of human deafness that represents 2-8% of all cases of congenital genetic deafness.

Ear wax removal South Devon

DFNB9 deafness is caused by mutations in the gene coding for otoferlin, a protein that plays a key role in transmitting sound information at the inner hair cell synapses. Mutant mice deficient in otoferlin are profoundly deaf as these synapses fail to release neurotransmitters in response to sound stimulation, despite the absence of detectable sensory epithelial defects. DFNB9 mice therefore constitute an appropriate model for testing the efficacy of viral gene therapy when it is administered at a late stage. However, as AAVs have limited DNA packaging capacity (approximately 4.7 kilobase (kb)), it is difficult to use this technique for genes whose coding region (cDNA) exceeds 5 kb, such as the gene coding for otoferlin, which has a 6 kb coding region. The scientists have overcome this limitation by adapting an AAV approach known as dual AAV strategy because it uses two different recombinant vectors, one containing the 5’-end and the other the 3’-end of the otoferlin cDNA.

A single intracochlear injection of the vector pair in adult mutant mice was used to reconstruct the otoferlin coding region by recombining 5′ and 3′-end DNA segments, leading to long-term restoration of otoferlin expression in the inner hair cells, and then restored hearing.

Honiton hearing centre, Devon

The scientists have therefore obtained initial proof of the concept of viral transfer of fragmented cDNA in the cochlea using two vectors, showing that this approach can be used to produce otoferlin and durably correct the profound deafness phenotype in mice.

The outcomes achieved by the scientists suggest that the therapeutic window for local gene transfer in patients with DFNB9 congenital deafness could be wider than thought, and offers hope of extending these findings to other forms of deafness. These results are the subject of a patent application filed.

Hearing aids Tiverton, Devon

In addition to the institutions mentioned in the first paragraph, this research was funded by the French Foundation for Medical Research, the European Union (TREAT RUSH), and the French National Research Agency (EargenCure and Lifesenses LabEx).

Original Paper: Akil O, Dyka F, Calvet C, et al. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. PNAS. 2019. DOI: https://doi.org/10.1073/pnas.1817537116

Source: Institut Pasteur, PNAS

Image: Institute Pasteur